Effects of synbiotic therapy in mild-to-moderately active ulcerative colitis: A randomized placebo-controlled study

H, Kamarlı Altun; E, Akal Yıldız; Akın, Mete

doi:10.5152/tjg.2019.18356

Cited by 52 publications

(36 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The study showed an amelioration of the disease status of the synbiotic treated UC patients and a significant reduction of systemic inflammation as measured by serum CRP levels. These results support the use of synbiotics as an effective strategy to prevent the exacerbation of the disease in patients with mild-to-moderately active UC [93]. Nevertheless, although prebiotics have an excellent safety profile, they have been associated with symptoms of dose-dependent abdominal pain, flatulence, bloating, and diarrhea [134]; therefore, insoluble fibre intake is discouraged in the case of significant intestinal stenosis in IBD patients [135].…”

Section: Prebiotic Diets and Synbioticsmentioning

confidence: 63%

The Role of Gut Microbiota Biomodulators on Mucosal Immunity and Intestinal Inflammation

Amoroso

Perillo

Strati

et al. 2020

Cells

143

100

View full text Add to dashboard Cite

Alterations of the gut microbiota may cause dysregulated mucosal immune responses leading to the onset of inflammatory bowel diseases (IBD) in genetically susceptible hosts. Restoring immune homeostasis through the normalization of the gut microbiota is now considered a valuable therapeutic approach to treat IBD patients. The customization of microbe-targeted therapies, including antibiotics, prebiotics, live biotherapeutics and faecal microbiota transplantation, is therefore considered to support current therapies in IBD management. In this review, we will discuss recent advancements in the understanding of host−microbe interactions in IBD and the basis to promote homeostatic immune responses through microbe-targeted therapies. By considering gut microbiota dysbiosis as a key feature for the establishment of chronic inflammatory events, in the near future it will be suitable to design new cost-effective, physiologic, and patient-oriented therapeutic strategies for the treatment of IBD that can be applied in a personalized manner.

show abstract

Section: Prebiotic Diets and Synbioticsmentioning

confidence: 63%

The Role of Gut Microbiota Biomodulators on Mucosal Immunity and Intestinal Inflammation

Amoroso

Perillo

Strati

et al. 2020

Cells

143

100

View full text Add to dashboard Cite

show abstract

“…On the other hand, 40 patients with UC that received, for 8 weeks, a symbiotic composed of six probiotic strains ( Enterococcus faecium, Lactobacillus plantarum, Streptococcus thermophilus, Bifidobacterium lactis, Lactobacillus acidophilus, Bifidobacterium longum ) and FOS (a prebiotic, NBL Probiotic Optima), showed an improvement in clinical and endoscopic activity and a reduction in serum C-reactive protein (CRP). However, no significant changes were found in other inflammatory markers (levels of hemoglobin, leukocytes, neutrophils, lymphocytes, and thrombocytes, as well as the neutrophil-lymphocyte ratio) [ 75 ].…”

Section: Intestinal Epithelial Barrier Disordersmentioning

confidence: 99%

Bioactive Compounds in Food as a Current Therapeutic Approach to Maintain a Healthy Intestinal Epithelium

et al. 2021

View full text Add to dashboard Cite

The intestinal epithelium serves as an effective barrier against the external environment, hampering the passage of potentially harmful substances (such as pathogenic microbes) that could trigger an exacerbated host immune response. The integrity of this barrier is thus essential for the maintenance of proper intestinal homeostasis and efficient protective reactions against chemical and microbial challenges. The principal consequence of intestinal barrier defects is an increase in intestinal permeability, which leads to an increased influx of luminal stressors, such as pathogens, toxins, and allergens, which in turn trigger inflammation and immune response. The fine and fragile balance of intestinal homeostasis can be altered by multiple factors that regulate barrier function, many of which are poorly understood. This review will address the role of gut microbiota as well as food supplements (such as probiotics, prebiotics, and synbiotics) in modulating gut health and regulating intestinal barrier function. In particular, we will focus on three human pathologies: inflammatory bowel disease, irritable bowel syndrome, and food allergy.

show abstract

“…On the other hand, several studies show that mixed probiotics are more effective than using individual probiotics. The analysis of these clinical trials showed a significant benefit of probiotic use, especially when the strains were mixed [26,28,29,32,33]. These findings were previously demonstrated in pouchitis with the use of DSF [48,51,52].…”

Section: Efficacy Of the Probiotics In Ucmentioning

confidence: 66%

“…One of the nine trials, with a sample of 120 patients, compared probiotics with prebiotics and synbiotics for the induction of the remission of active UC [25], and the remaining eight trials were placebo-controlled [26][27][28][29][30][31][32][33]. Two trials presented a low bias risk [29,30].…”

Section: Efficacy Of the Probiotics To Induce Remission In Active Ucmentioning

confidence: 99%

“…The seven RCTs which were placebo-controlled contained a total of 639 patients with active UC [26][27][28][29][30][31][32][33]. In total, 201 out of 362 (55.52%) patients allocated to probiotics did not achieve remission, versus 271 out of 397 (68.26%) patients in the placebo group (RR to achieve remission = 0.81; 95% CI = 0.72-0.91), with heterogeneity among the studies (I 2 = 32%, p = 0.16).…”

Section: Efficacy Of the Probiotics To Induce Remission In Active Ucmentioning

confidence: 99%

See 1 more Smart Citation

Probiotics as a Coadjuvant Factor in Active or Quiescent Inflammatory Bowel Disease of Adults—A Meta-Analytical Study

et al. 2020

View full text Add to dashboard Cite

(1) Background: Inflammatory bowel diseases are pathologies of unknown etiology and auto-immune pathogenia. The use of probiotics is studied in order to increase the arsenal of treatments. The aim was to assess the efficacy of the probiotics in these diseases in the active or quiescent phases; (2) Methods: A systematic review with meta-analysis was performed by an exhaustive bibliographic search in Medline, Cinahl, Embase, Scopus, Web of Science, and Cochrane Library. The inclusion criteria were studies of more than 10 years, English/Spanish, clinical trials, and involving human beings. Relative risk was used to compare efficacy, which was meta-analyzed using a fixed effects model. Heterogeneity was evaluated with the Higgins I2 test; (3) Results: Nineteen studies were included in the systematic review and 17 in the meta-analysis, with a total of 1537 patients (nexperimental group = 762; nplacebo group = 775). There are significant remission differences in ulcerative colitis (relative risk (RR) = 0.81; 95% CI = 0.72–0.91; I2 = 32%; p = 0.16). However, no significant differences were found in the use of probiotics for the prevention of ulcerative colitis, and for the remission of Crohn’s disease; (4) Conclusions: There are data showing an additional beneficial effect of probiotics on active ulcerative colitis. More and better studies are needed which assess its possible therapeutic efficacy for quiescent ulcerative colitis and for Crohn’s disease.

show abstract

Effects of synbiotic therapy in mild-to-moderately active ulcerative colitis: A randomized placebo-controlled study

Cited by 52 publications

References 20 publications

The Role of Gut Microbiota Biomodulators on Mucosal Immunity and Intestinal Inflammation

The Role of Gut Microbiota Biomodulators on Mucosal Immunity and Intestinal Inflammation

Bioactive Compounds in Food as a Current Therapeutic Approach to Maintain a Healthy Intestinal Epithelium

Probiotics as a Coadjuvant Factor in Active or Quiescent Inflammatory Bowel Disease of Adults—A Meta-Analytical Study

Contact Info

Product

Resources

About